NIKKEI 225
26,153.81 +218.19 (+0.84%) HANG SENG
21,830.35 -29.44 (-0.13%) CRUDE OIL
110.30 +1.87 (+1.72%) GOLD FUTURES
1,807.40 +5.90 (+0.33%) DOW
31,097.26 +321.86 (+1.05%) BTC-GBP
16,291.68 +412.39 (+2.60%)
MorphoSys AG (MOR.DE)
| Previous close | 19.40 |
| Open | 19.33 |
| Bid | 19.26 x 1500 |
| Ask | 19.31 x 8800 |
| Day's range | 18.92 - 19.49 |
| 52-week range | 16.45 - 67.46 |
| Volume | |
| Avg. volume | 158,755 |
| Market cap | 659.092M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer
MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.
- Motley Fool
MorphoSys AG (MOR) Q1 2022 Earnings Call Transcript
My name is Julia Neugebauer, senior director investor relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2022 financial results conference call. Joining me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.
- Zacks
Wall Street Analysts Believe MorphoSys AG Unsponsored ADR (MOR) Could Rally 213%: Here's is How to Trade
The mean of analysts' price targets for MorphoSys AG Unsponsored ADR (MOR) points to a 213.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
